Post-earnings recap
Reported
Mon, Aug 7, 2023
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
CRISPR Therapeutics reported a larger-than-expected loss per share, which surprised investors positively, but the lack of revenue figures and guidance led to a stock decline of 5.14%. The market reaction reflects ongoing concerns about the company's performance and future outlook. Investors may be cautious as management did not provide specific guidance for upcoming quarters.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.98 | N/A | +55.05% |
| Revenue | N/A | N/A | N/A |
Management expressed caution regarding current market conditions. They reiterated their commitment to research and development despite the challenges.
Management highlighted ongoing challenges in the market.
They emphasized the importance of continued investment in R&D.
There was no specific guidance provided for future quarters.